Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05704842 · ClinicalTrials.gov registry record · NA

Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy

A NA study of Breast Cancer, sponsored by Virtua Health.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05704842 is a NA study of Breast Cancer that is actively recruiting participants, run by Virtua Health. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05704842, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Virtua Health.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Assess feasibility of home exercise in reducing fatigue in subjects with breast cancer receiving curative intent chemotherapy. Subjects are randomized to control (no exercise) or intervention group (exercise). The PRO-CTCAE tool and FACIT Fatigue Scale are used to collect patient reported outcomes. Subjects submit data via mobile phone, tablet or computer. Assessments are weekly during chemotherapy (10-20 wks), at end of chemotherapy and 1, 3 and 6 months after chemotherapy.

Conditions Studied

Interventions

  • BEHAVIORAL Exercise

Study Locations (1)

New Jersey

  • Virtua Health - Voorhees Township

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-12-22
Est. Completion 2026-06-01
Phase NA

Sponsor

Virtua Health

9 total trials

What the Registry Record Tells You About NCT05704842

The ClinicalTrials.gov registry entry for NCT05704842 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Virtua Health, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.

NCT05704842 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT05704842 about?

NCT05704842 is a clinical study titled "Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy". Assess feasibility of home exercise in reducing fatigue in subjects with breast cancer receiving curative intent chemotherapy. Subjects are randomized to control (no exercise) or intervention group (exercise). The PRO-CTCAE tool and FACIT Fatigue Scale are used to collect patient reported outcomes. ...

What is the current status of trial NCT05704842?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2022-12-22. Estimated completion is 2026-06-01.

What conditions does trial NCT05704842 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05704842?

The interventions under investigation include: Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT05704842?

This trial is sponsored by Virtua Health, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05704842 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.